Inmed selects IVT formulation of INM-089 for dry AMD

Feb. 4, 2025

Inmed Pharmaceuticals Inc. has selected an intravitreal (IVT) formulation for INM-089 as a drug candidate to be utilized in the company’s ongoing development program targeting the treatment of dry age-related macular degeneration (AMD).

BioWorld Science Ocular

NIH changes set industry up for workforce, ideas drought

BioWorld

On March 1, 2025, former NIH director Francis Collins’ announced that he had fully resigned from the NIH, where he continued to lead a laboratory after his...

Today's news in brief

BioWorld

BioWorld briefs for March 14, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for March 14, 2025

At CROI, HIV cure trials raise hopes for broader applicability

BioWorld

At the 2025 meeting of the Conference on Retroviruses and Opportunistic Infections (CROI) it was the best of times, it was the worst of times. On the first full...

Hummingbird migrates ADCs, tech to newco Callio’s $187M debut

BioWorld

Antibody-drug conjugate (ADC)-focused Callio Therapeutics debuted on March 3 with the closing of a $187 million series A financing round based on cancer drug...